Seaport Therapeutics (SPTX) Corporate presentation summary

Market opportunity and unmet need

• Over 1 billion people globally live with mental illness, with major depressive disorder (MDD) and anxiety disorders affecting hundreds of millions and often co-occurring.

• Current neuropsychiatric medications have limitations, including modest efficacy, slow onset, and unfavorable side effects such as sexual dysfunction and weight gain.

• Suicide risk is significantly elevated in people with MDD, highlighting the urgent need for better treatments.

Leadership and team expertise

• Leadership team includes experienced executives with successful track records in neuropsychiatry drug development and commercialization.

• Key members have led major exits and approvals, such as Karuna's $14B acquisition and the development of drugs like Zyprexa and Cymbalta.

Platform technology and innovation

• The proprietary Glyph™ platform enables oral delivery of drugs previously limited by high first-pass metabolism, improving bioavailability and reducing hepatotoxicity.

• The platform leverages lymphatic transport to bypass the liver, generating new intellectual property and reducing pharmacokinetic variability.

• Over 24 small molecules have been created using this technology, with strong composition of matter IP.